Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation як ҳолати пӯст аст, ки бо зиёд шудани пигмент дар пӯст пас аз илтиҳоби пӯст тавсиф мешавад. Postinflammatory hyperpigmentation метавонад аз таъсири дуру дарози офтоб, илтиҳоб ё ҷароҳатҳои дигари пӯст, аз ҷумла осебҳои марбут ба акне ба вуҷуд ояд. Одамони дорои оҳангҳои пӯсти ториктар одатан ба гиперпигментация бо таъсири аз ҳад зиёди офтоб бештар майл доранд.
☆ Дар натиҷаҳои соли 2022 Stiftung Warentest аз Олмон, қаноатмандии истеъмолкунандагон аз ModelDerm нисбат ба машваратҳои пулакии телетиб танҳо каме пасттар буд.
References
Postinflammatory hyperpigmentation (PIH) як мушкилии зуд-зуд пӯст аст, ки пас аз илтиҳоби пӯст ё осеби пӯст рух медиҳад. Он одатан муддати тӯлонӣ давом мекунад ва дар одамоне, ки рангҳои пӯст доранд, бадтар аст (Fitzpatrick skin types III–VI) . Гарчанде ки он аксар вақт худ аз худ беҳтар мешавад, ин метавонад каме вақт гирад, аз ин рӯ табобат аксар вақт барои муддати тӯлонӣ лозим аст. Якҷоя кардани табобатҳои гуногун беҳтар аст.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation як оқибати маъмулии илтиҳоби пӯст аст. Он ба одамони сиёҳпӯст бештар ва зуд-зуд таъсир мерасонад. Таҳқиқотҳо нишон медиҳанд, ки масъалаҳое ба монанди postinflammatory hyperpigmentation яке аз сабабҳои асосии он аст, ки одамоне, ки ранги пӯст доранд, ба нигоҳубини дерматологӣ муроҷиат мекунанд. Табобати барвақтӣ барои ҳалли postinflammatory hyperpigmentation муҳим аст ва одатан бо идоракунии ҳолати ибтидоии илтиҳобӣ оғоз меёбад. Хатти якуми табобат маъмулан истифодаи агентҳои маҳаллиро дар бар мегирад, ки пӯстро бо офтоб барои муҳофизат сабук мекунанд. Ин агентҳо, ба монанди hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , метавонанд пигментацияи аз ҳад зиёдро самаранок коҳиш диҳанд. Илова бар ин, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy инчунин ҳамчун агентҳои депигментатсия истифода мешаванд, ки табобатҳои нав пайдо мешаванд. Гарчанде ки табобатҳои актуалӣ одатан барои гиперпигментацияи сатҳи рӯизаминӣ самараноканд, равандҳо (laser, chemical peel) метавонанд барои ҳолатҳои якрав зарур бошанд. Муҳим аст, ки бо ин табобатҳо эҳтиёткор бошед, то аз хашм ва бадтар шудани postinflammatory hyperpigmentation пешгирӣ кунед.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
